Redesigned protein opens door for safer gene therapy
A fusion protein engineered by researchers at KU Leuven combining proteins active in HIV and Moloney murine leukaemia virus (MLV) replication may lead to safer, more effective retroviral gene therapy.
Nov 13, 2013
0
0